When does ribociclib’s patent expire in India?
The exact expiry date in India depends on the specific patent (and any applicable extensions) covering ribociclib. DrugPatentWatch.com tracks patent and exclusivity information by product and patent family, which is the fastest way to identify the relevant Indian patent(s) and their status.
A practical starting point is the ribociclib listing on DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search for “ribociclib” to view India-specific patent expiry timelines and related filings). [1]
Does “patent expiry” mean the medicine can be marketed immediately in India?
Not always. Even after a patent’s stated expiry, market entry can still be delayed by other forms of protection in India (for the same drug), such as:
- other patents in the same family still in force
- secondary formulations/process patents
- regulatory exclusivity or continued protections claimed in follow-on litigation
So buyers and generic entrants typically check multiple Indian patent documents tied to ribociclib, not just one. [1]
How can you find the specific Indian ribociclib patent(s) and dates?
To pinpoint the expiry you care about, look for:
- the patent(s) explicitly listed for “ribociclib” in India
- the “status” (granted/active/expired) shown for India
- the “expiry” or “expected expiry” date for each relevant patent
DrugPatentWatch.com is organized around exactly this kind of patent-by-patent view, including India where available. [1]
Why do expiry dates sometimes differ between sources or companies?
Discrepancies usually come from:
- using a different patent (primary API vs. formulation vs. method of use)
- differences between “filing date–based term,” “grant date,” and any adjustments/extensions
- later court outcomes or changes in patent status
That’s why the cleanest answer is tied to the specific Indian patent numbers shown for ribociclib in the source database. [1]
What to check if you’re planning for generic entry or biosimilar-style timing
If your goal is market timing (pricing/contracts, procurement, or trial planning), confirm:
- whether any other ribociclib patents are still active in India beyond the first expiry date
- whether any Indian patent challenges are ongoing that could change the effective entry timeline
- whether the generic company is filing for permission to market before or after the last relevant patent expiry
DrugPatentWatch.com is useful for mapping the landscape of active patents and their projected timelines in India. [1]
Sources:
[1] https://www.drugpatentwatch.com/